1. Home
  2. Directory
  3. California
  4. Los Angeles
  5. Dermatology
  6. NPI Profile
  7. Prescriptions 1124026554

DR. HOWARD L SOFEN M.D.
Prescription History 1124026554
Dermatology in Los Angeles, CA


Quality Rating: 0 out of 100 score

NPI Status: Active since July 10, 2005

Contact Information

8930 S SEPULVEDA BLVD
#114
LOS ANGELES, CA
ZIP 90045
Phone: (310) 337-7171
Fax: (310) 337-1081

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. HOWARD L SOFEN M.D., an active Dermatology specialist practicing in Los Angeles, CA. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 24 documented patient claims. Among these therapy options, the most frequently utilized medication is Cimzia, which accounts for 13 claims alone.

Medication Index

C
O
No matching medications currently found on file.

Cimzia

Generic Formulation: Certolizumab PegolSpecialty: Dermatology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 364
CA State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills22.0
Peer Average Days Supply622
Conservative Utilization

This provider writes prescriptions for this formulation 35.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $78,032.62 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,002.51

State Avg Cost Per Claim

$6,265.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.

Therapeutic Applications

This medication is used to reduce pain and swelling due to certain inflammatory conditions (such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis). Some brands may also be used to treat a certain type of spine condition (axial spondyloarthritis) or a certain bowel condition (Crohn's disease). Certolizumab belongs to a class of drugs known as tumor necrosis factor (TNF) blockers. It works by blocking TNF, a substance made by the body that causes inflammation.

Olumiant

Generic Formulation: BaricitinibSpecialty: Dermatology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
CA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills20.8
Peer Average Days Supply625
Conservative Utilization

This provider writes prescriptions for this formulation 38.9% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $30,026.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,729.71

State Avg Cost Per Claim

$3,039.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Baricitinib is used to treat rheumatoid arthritis. It helps decrease pain, tenderness, and swelling in the joints. It is also used to treat a certain immune disorder which causes hair loss (alopecia areata). In the US, baricitinib is also being used to treat coronavirus disease (COVID-19). It is used in certain patients in the hospital who need supplemental oxygen (including patients on a mechanical ventilator).

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. HOWARD L SOFEN M.D. provides transparency into local medical care patterns within Los Angeles, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Dermatology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.